UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

The New England journal of medicine, 2005-03, Vol.352 (11), p.1092-1102

2005

Volltextzugriff (PDF)

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

JAMA : the journal of the American Medical Association, 1999-11, Vol.282 (20), p.1929

1999

Volltextzugriff (PDF)

Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis

Journal of rheumatology, 2000-11, Vol.27 (11), p.2635

2000

Volltextzugriff (PDF)

A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain

Pain (Amsterdam), 2016-01, Vol.157 (1), p.264-272

2016

Volltextzugriff (PDF)

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis

Current medical research and opinion, 2005-05, Vol.21 (5), p.715-722

2005

Volltextzugriff (PDF)

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

The Lancet (British edition), 2006-11, Vol.368 (9549), p.1771-1781

2006

Volltextzugriff (PDF)

Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs

Current medical research and opinion, 2004-12, Vol.20 (12), p.1899-1908

2004

Volltextzugriff (PDF)

A Comparison of Adverse Renovascular Experiences Among Osteoarthritis Patients Treated with Rofecoxib and Comparator Non-selective Non-steroidal Anti-inflammatory Agents

Current medical research and opinion, 2002, Vol.18 (2), p.82-91

2002

Volltextzugriff (PDF)

Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints

Journal of rheumatology, 2001-12, Vol.28 (12), p.2700

2001

Volltextzugriff (PDF)

Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement

Osteoarthritis and cartilage, 2003-07, Vol.11 (7), p.499-507

2003

Volltextzugriff (PDF)

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis

The American heart journal, 2006-08, Vol.152 (2), p.237-245

2006

Volltextzugriff (PDF)

The Pain Quality Response Profile of Pregabalin in the Treatment of Neuropathic Pain

The Clinical journal of pain, 2012-10, Vol.28 (8), p.683-686

2012

Volltextzugriff (PDF)

Predicting Response to Pregabalin from Pretreatment Pain Quality: Clinical Applications of the Pain Quality Assessment Scale

Pain medicine (Malden, Mass.), 2013-04, Vol.14 (4), p.526-532

2013

Volltextzugriff (PDF)

Evaluation of an Adaptive Maximizing Design Study Based on Clinical Utility Versus Morphine for TRV130 Proof-of-Concept and Dose-Regimen Finding in Patients With Postoperative Pain After Bunionectomy

Therapeutic innovation & regulatory science, 2015-09, Vol.49 (5), p.756-766

2015

Volltextzugriff (PDF)

A walking model to assess the onset of analgesia in osteoarthritis knee pain

Osteoarthritis and cartilage, 2010-05, Vol.18 (5), p.646-653

2010

Volltextzugriff (PDF)

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects

The American journal of medicine, 2000-08, Vol.109 (3), p.201-206

2000

Volltextzugriff (PDF)

The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis

Current medical research and opinion, 2004-10, Vol.20 (10), p.1539-1548

2004

Volltextzugriff (PDF)

Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension

Journal of rheumatology, 2006-05, Vol.33 (5), p.985

2006

Volltextzugriff (PDF)

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

Alimentary pharmacology & therapeutics, 2001-10, Vol.15 (10), p.1593-1601

2001

Volltextzugriff (PDF)

Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX‐2 selective Inhibitor etoricoxib

Current medical research and opinion, 2006-12, Vol.22 (12), p.2365-2374

2006

Volltextzugriff (PDF)

Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men

The journal of clinical endocrinology and metabolism, 1996-08, Vol.81 (8), p.2776-2782

1996

Volltextzugriff (PDF)

Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis

The American journal of managed care, 2001-06, Vol.7 (6), p.609-616

2001

Volltextzugriff (PDF)

Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man

Neuroendocrinology, 1997-10, Vol.66 (4), p.278-286

1997

Volltextzugriff (PDF)

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis

Archives of internal medicine (1960), 2000-10, Vol.160 (19), p.2998

2000

Volltextzugriff (PDF)

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study

Annals of internal medicine, 1987-11, Vol.107 (5), p.609

1987

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(68)

Sprache

Englisch
(68)

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Life Sciences & Biomedicine
(47)
Humans
(43)
Male
(32)
Female
(26)
Biological And Medical Sciences
(25)
Medical Sciences
(24)
Middle Aged
(24)
Adult
(23)
Double-Blind Method
(21)
Pharmacology. Drug Treatments
(18)
Physical Sciences
(17)
Physics
(17)
Physics, Particles & Fields
(17)
Aged
(16)
General & Internal Medicine
(14)
Medicine, General & Internal
(14)
Osteoarthritis - Drug Therapy
(13)
Cyclooxygenase Inhibitors - Therapeutic Use
(12)
Pharmacology & Pharmacy
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis

A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs

A Comparison of Adverse Renovascular Experiences Among Osteoarthritis Patients Treated with Rofecoxib and Comparator Non-selective Non-steroidal Anti-inflammatory Agents

Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints

Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis

The Pain Quality Response Profile of Pregabalin in the Treatment of Neuropathic Pain

Predicting Response to Pregabalin from Pretreatment Pain Quality: Clinical Applications of the Pain Quality Assessment Scale

Evaluation of an Adaptive Maximizing Design Study Based on Clinical Utility Versus Morphine for TRV130 Proof-of-Concept and Dose-Regimen Finding in Patients With Postoperative Pain After Bunionectomy

A walking model to assess the onset of analgesia in osteoarthritis knee pain

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects

The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis

Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX‐2 selective Inhibitor etoricoxib

Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men

Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis

Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study

Suchergebnisse filtern